SCHEMBL11997499

CO[C@H]1OC(COS(=O)(=O)O)[C@@H](O[C@H]2C[C@H](O)[C@@H](O[C@@H]3OC(COS(=O)(=O)O)[C@@H](O[C@H]4C[C@H](O)[C@@H](O[C@@H]5OC(COS(=O)(=O)O)[C@@H](O[C@H]6C[C@H](O)[C@@H](O[C@@H]7OC(COS(=O)(=O)O)[C@@H](O[C@H]8C[C@H](O)[C@H](O)CO8)[C@H](O)C7NC(C)=O)CO6)[C@H](O)C5NC(C)=O)CO4)[C@H](O)C3NC(C)=O)CO2)[C@H](O)C1NC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	F10	P00742	2/20	0.40

▸	CD69	Q07108	1/20	0.36

▸	BMP2	P12643	2/20	0.36

▸	VEGFA	P15692	2/20	0.36

▸	CXCL12	P48061	2/20	0.36

▸	SHH	Q15465	2/20	0.36

▸	BDNF	P23560	3/20	0.35

▸	HPSE	Q9Y251	2/20	0.35

▸	PTN	P21246	2/20	0.35

▸	MDK	P21741	2/20	0.35

▸	LGALS3	P17931	6/20	0.35

▸	LGALS7; LGALS7B	P47929	2/20	0.35

▸	LGALS1	P09382	1/20	0.35

▸	MMP9	P14780	1/20	0.34

▸	MMP12	P39900	1/20	0.34

▸	LGALS9	O00182	2/20	0.34

▸	IFNG	P01579	1/20	0.33

▸	PF4	P02776	1/20	0.33

▸	CCL2	P13500	1/20	0.33

▸	SELP	P16109	1/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL11997501	0.97	CD69 (0.40)	F10CD69BMP2VEGFACXCL12
SCHEMBL11997500	0.97	CD69 (0.40)	F10CD69BMP2VEGFACXCL12
SCHEMBL11997502	0.97	CD69 (0.40)	F10CD69BMP2VEGFACXCL12
SCHEMBL11997503	0.97	CD69 (0.40)	F10CD69BMP2VEGFACXCL12
SCHEMBL16656569	0.92	F10 (0.37)	F10CD69BMP2VEGFACXCL12
SCHEMBL16656568	0.92	F10 (0.37)	F10CD69BMP2VEGFACXCL12
SCHEMBL11997493	0.88	VEGFA (0.50)	CD69BMP2VEGFACXCL12SHH
SCHEMBL11997497	0.88	VEGFA (0.49)	CD69BMP2VEGFACXCL12SHH
SCHEMBL11997512	0.85	F10 (0.39)	F10
SCHEMBL11997463	0.83	FGF1 (0.35)	F10HPSEFGF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9012413-B2	FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof	SANOFI (FR)	2015-04-21	—	—	US	disclosed
US-20120214754-A1	FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	SANOFI (FR)	2012-08-23	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120214754-A1	FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF	FGFR1, FGF2, FGFR3	F10 597/4885CD69 1406/4885BMP2 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.